Envisagenics

Envisagenics is an AI-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics. The company offers SpliceCore, a cloud-based platform that is experimentally validated to predict and prioritize RNA splicing events as therapeutic targets, using machine learning algorithms to analyze RNA sequencing data and identify disease-relevant splicing changes. The platform integrates bioinformatics, AI, and biological expertise to accelerate drug discovery for conditions driven by RNA splicing errors, including cancer, neurodegenerative diseases, and rare genetic disorders. Envisagenics leverages its proprietary technology to identify new therapeutic targets and develop RNA-based drug candidates, partnering with pharmaceutical companies to advance precision medicine approaches. Founded in 2014 and headquartered in Long Island City, New York, Envisagenics has raised approximately $46.8 million in Series B funding from investors including SV Angel, Dolby Family Ventures, Dynamk Capital, The Cosine Group, and Third Kind Venture Capital.